Department of Pharmaceutical Chemistry, ASBASJSM College of Pharmacy, Bela, Ropar 140111, Punjab, India.
Eur J Med Chem. 2011 Jun;46(6):2327-46. doi: 10.1016/j.ejmech.2011.03.015. Epub 2011 Mar 15.
The synthesis of some 2-furano-4(3H)-quinazolinones, diamides (open ring quinazolines), quinoxalines and their biological evaluation as antitumor agents using National Cancer Institute (NCI) disease oriented antitumor screen protocol are investigated. Among the synthesize compounds, seventeen compounds were granted NSC code and screened at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10(-5) M) in full NCI 60 cell panel. Among the selected compounds, 3-(2-chloro benzylideneamine)-2-(furan-2-yl) quinazoline-4(3h)-one 21 was found to be the most active candidate of the series at five dose level screening against Ovarian OVCAR-4 and Non-small cell lung cancer NCI-H522 with GI50 1.82 & 2.14 μM respectively. Rational approach and QSAR techniques enabled the understanding of the pharmacophoric requirement for quinazoline, diamides and quinoxaline derivatives.
研究了一些 2-呋喃-4(3H)-喹唑啉酮、二酰胺(开环喹唑啉)、喹喔啉及其作为抗肿瘤剂的生物评价,采用国立癌症研究所(NCI)面向疾病的抗肿瘤筛选方案。在合成的化合物中,有 17 种化合物获得 NSC 编号,并在美国国立癌症研究所(NCI)进行了筛选,在全 NCI 60 细胞组中以单一高剂量(10(-5)M)进行了抗癌活性筛选。在所选择的化合物中,3-(2-氯亚苄基胺)-2-(呋喃-2-基)喹唑啉-4(3h)-酮 21 被发现是该系列中对卵巢癌 OVCAR-4 和非小细胞肺癌 NCI-H522 最有效的候选化合物,GI50 分别为 1.82 和 2.14 μM。合理的方法和 QSAR 技术使人们能够理解对喹唑啉、二酰胺和喹喔啉衍生物的药效团要求。